PMID- 33057993
OWN - NLM
STAT- MEDLINE
DCOM- 20210602
LR  - 20210602
IS  - 1573-4978 (Electronic)
IS  - 0301-4851 (Linking)
VI  - 47
IP  - 11
DP  - 2020 Nov
TI  - Chromosomal instability reducing effect of paclitaxel and lapatinib in mouse 
      embryonic stem cells with chromosomal abnormality.
PG  - 8605-8614
LID - 10.1007/s11033-020-05903-8 [doi]
AB  - Chromosomal abnormalities, as a frequent phenomenon in cultured embryonic stem 
      cells (ESCs), is a major obstacle in the ESC application in regenerative 
      medicine. Recent studies showed that aneuploid embryonic stem cells of humans and 
      mice are more vulnerable to anticancer drugs, compared with normal cells. The aim 
      of the current study was to evaluate effects of three anticancer drugs, 
      paclitaxel, lapatinib and bortezomib, on mouse embryonic stem cells (mESCs) as a 
      suitable and available model. To assess in vitro cell toxicity, two mESC lines 
      were treated with the aforementioned drugs. Using G-band karyotyping and 
      micronucleus assay, the effect of anticancer drugs in terms of reduction of 
      chromosomal instability in the mESCs was evaluated in control and treatment 
      groups. Also, apoptosis rate of both groups was estimated by 
      FITC-Annexin V/Propidium Iodide (PI) double staining. In addition, the effect of 
      these three drugs in maintaining the pluripotency was assessed through alkaline 
      phosphatase assay and quantification of the expression of three key pluripotency 
      genes, Nanog, Pou5f1 and Sox-2 was performed using Real Time PCR. The rate of 
      numerical abnormalities after treatment with paclitaxel and lapatinib was lower 
      than the control group. The expression level of pluripotency genes exhibited no 
      significant difference between control and treatment groups. Administration of 
      paclitaxel and lapatinib to the mESCs culture at an appropriate dose and in a 
      timely manner could decrease chromosome stability without affecting pluripotency.
FAU - Mirzaei-Seresht, Banafsheh
AU  - Mirzaei-Seresht B
AUID- ORCID: 0000-0002-7823-1242
AD  - Department of Genetics, Reproductive Biomedicine Research Center, Royan Institute 
      for Reproductive Biomedicine, ACECR, No. 2, Hafez St., Banihashem St., Resalat 
      Highway, P.O.Box:16635-148, Tehran, Iran.
AD  - Department of Genetics, Faculty of Biological Science, Shahid Beheshti 
      University, Tehran, Iran.
FAU - Bazrgar, Masood
AU  - Bazrgar M
AUID- ORCID: 0000-0002-5453-9576
AD  - Department of Genetics, Reproductive Biomedicine Research Center, Royan Institute 
      for Reproductive Biomedicine, ACECR, No. 2, Hafez St., Banihashem St., Resalat 
      Highway, P.O.Box:16635-148, Tehran, Iran. mbazrgar@royaninstitute.org.
FAU - Sheidai, Masoud
AU  - Sheidai M
AD  - Department of Genetics, Faculty of Biological Science, Shahid Beheshti 
      University, Tehran, Iran.
FAU - Hassani, Seyedeh-Nafiseh
AU  - Hassani SN
AUID- ORCID: 0000-0001-5047-8406
AD  - Department of Stem Cell and Developmental Biology, Cell Science Research Center, 
      Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
FAU - Masoudi, Najmeh Sadat
AU  - Masoudi NS
AUID- ORCID: 0000-0002-6337-6625
AD  - Department of Genetics, Reproductive Biomedicine Research Center, Royan Institute 
      for Reproductive Biomedicine, ACECR, No. 2, Hafez St., Banihashem St., Resalat 
      Highway, P.O.Box:16635-148, Tehran, Iran.
FAU - Mollammohammadi, Sepideh
AU  - Mollammohammadi S
AUID- ORCID: 0000-0003-3389-8833
AD  - Department of Stem Cell and Developmental Biology, Cell Science Research Center, 
      Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
LA  - eng
PT  - Journal Article
DEP - 20201015
PL  - Netherlands
TA  - Mol Biol Rep
JT  - Molecular biology reports
JID - 0403234
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Nanog Homeobox Protein)
RN  - 0 (Nanog protein, mouse)
RN  - 0 (Octamer Transcription Factor-3)
RN  - 0 (Pou5f1 protein, mouse)
RN  - 0 (SOXB1 Transcription Factors)
RN  - 0 (Sox2 protein, mouse)
RN  - 0VUA21238F (Lapatinib)
RN  - 69G8BD63PP (Bortezomib)
RN  - P88XT4IS4D (Paclitaxel)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/*pharmacology
MH  - Apoptosis/drug effects
MH  - Bortezomib/pharmacology
MH  - Cell Line
MH  - Chromosomal Instability/*drug effects
MH  - Lapatinib/*pharmacology
MH  - Mice
MH  - Mouse Embryonic Stem Cells/*drug effects
MH  - Nanog Homeobox Protein/metabolism
MH  - Octamer Transcription Factor-3/metabolism
MH  - Paclitaxel/*pharmacology
MH  - SOXB1 Transcription Factors/metabolism
OTO - NOTNLM
OT  - Bortezomib
OT  - Chromosomal instability
OT  - Lapatinib
OT  - Mouse embryonic stem cells
OT  - Paclitaxel
EDAT- 2020/10/16 06:00
MHDA- 2021/06/03 06:00
CRDT- 2020/10/15 17:39
PHST- 2020/04/03 00:00 [received]
PHST- 2020/10/07 00:00 [accepted]
PHST- 2020/10/16 06:00 [pubmed]
PHST- 2021/06/03 06:00 [medline]
PHST- 2020/10/15 17:39 [entrez]
AID - 10.1007/s11033-020-05903-8 [pii]
AID - 10.1007/s11033-020-05903-8 [doi]
PST - ppublish
SO  - Mol Biol Rep. 2020 Nov;47(11):8605-8614. doi: 10.1007/s11033-020-05903-8. Epub 
      2020 Oct 15.